FLDM - Fluidigm Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.46
+0.16 (+1.42%)
As of 2:11PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close11.30
Open11.30
Bid11.34 x 1000
Ask11.35 x 800
Day's Range11.02 - 11.51
52 Week Range5.50 - 14.90
Volume286,959
Avg. Volume878,887
Market Cap790.968M
Beta (3Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-1.60
Earnings DateAug 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.40
Trade prices are not sourced from all markets
  • Update: Fluidigm (NASDAQ:FLDM) Stock Gained 90% In The Last Year
    Simply Wall St.10 days ago

    Update: Fluidigm (NASDAQ:FLDM) Stock Gained 90% In The Last Year

    While Fluidigm Corporation (NASDAQ:FLDM) shareholders are probably generally happy, the stock hasn't had particularly...

  • GlobeNewswire15 days ago

    Fluidigm Announces Conference Call and Webcast of Second Quarter 2019 Financial Results

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report second quarter 2019 financial results on Thursday, August 1, 2019, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on August 1, 2019, to discuss second quarter financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.

  • GlobeNewswire28 days ago

    Fluidigm Highlights New Advancements in Deep Cellular Profiling from Circulation to Tissue at CYTO 2019

    SOUTH SAN FRANCISCO, Calif., June 20, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.

  • GlobeNewswire29 days ago

    Fluidigm Introduces Three Imaging Mass Cytometry Panel Kits and Advanced CyTOF Software to Accelerate Immuno-Oncology Research

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will introduce three new Imaging Mass Cytometry™ Maxpar® panel kits and an advanced CyTOF® software solution in the third quarter to power immuno-oncology research. Imaging Mass Cytometry is rapidly advancing our understanding of health and disease by empowering researchers around the globe to deeply profile cellular phenotypes in tumors and tissues. The new ready-to-go Maxpar panel kits for immuno-oncology studies can enable researchers to rapidly profile immune infiltrates across a range of human cancer types and treatment modalities with Imaging Mass Cytometry.

  • GlobeNewswirelast month

    Fluidigm Scales Highly Multiplexed Cell Analysis with Introduction of Seven New Metal Markers

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will introduce seven new cadmium metal labeling kits for mass cytometry in Q3. Representing the first of a series of new metal isotopes in development, these new isotopes will empower researchers to easily design and customize larger panels to advance biomarker discovery and therapeutic development. Mass cytometry is an industry-leading tool for deep interrogation of cellular phenotypes and function in health and disease.

  • GlobeNewswirelast month

    Oncology Researcher Andrew Quong Joins Fluidigm as Chief Science Officer

    Quong will lead the company’s strategy for the generation of bold scientific insights in immunology, immuno-oncology and other frontiers of human health based on Fluidigm® technology. Quong was most recently Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research, a federally funded research and development center sponsored by the National Cancer Institute.

  • GlobeNewswire2 months ago

    Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Fluidigm Corporation (FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 31, 2019, under Fluidigm’s 2017 Inducement Award Plan (“Plan”), as a material inducement to employment to an individual hired by Fluidigm in May 2019. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).

  • GlobeNewswire2 months ago

    Fluidigm Introduces Advanta RNA Fusions NGS Library Prep Assay to Accelerate Translational and Clinical Cancer Research

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today introduced the Advanta™ RNA Fusions NGS Library Prep Assay for detection of over 380 gene fusion pairs from solid tumors and hematological cancers. Developed to fuel new advances in translational and clinical cancer research, the assay uniquely empowers researchers to interrogate gene fusions from a wide range of cancer types using a simple and highly efficient automated NGS library prep workflow.

  • GlobeNewswire2 months ago

    Fluidigm Introduces Automated Advanta Solid Tumor NGS Library Prep Assay Using Microfluidics Technology

    SOUTH SAN FRANCISCO, Calif., May 29, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.

  • Hedge Funds Have Never Been This Bullish On Fluidigm Corporation (FLDM)
    Insider Monkey2 months ago

    Hedge Funds Have Never Been This Bullish On Fluidigm Corporation (FLDM)

    Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors […]

  • GlobeNewswire2 months ago

    Fluidigm to Participate in Upcoming Health Care Investor Conferences

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor conferences. Chris Linthwaite, President and Chief Executive Officer, will participate in a fireside chat regarding Fluidigm’s business strategy and financial performance on Tuesday, May 21, 2019 at 11:30 ET at the UBS Global Healthcare Conference in New York. Vikram Jog, Chief Financial Officer, is scheduled to present on Tuesday, June 4, 2019, at 1:30 pm ET regarding Fluidigm’s business strategy and financial performance at the Jefferies 2019 Healthcare Conference in New York.

  • Fluidigm Delivers Growth Where It Matters Most in Q1 2019
    Motley Fool2 months ago

    Fluidigm Delivers Growth Where It Matters Most in Q1 2019

    The decision to retire $150 million in convertible debt caught the market off guard, but the business made progress on its long-term goals.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FLDM earnings conference call or presentation 2-May-19 9:00pm GMT

    Q1 2019 Fluidigm Corp Earnings Call

  • Zacks2 months ago

    Stocks Soar on Strong Jobs Report; NASDAQ at New High

    Stocks Soar on Strong Jobs Report; NASDAQ at New High

  • Here's Why Fluidigm Shares Fell as Much as 14.4% Today
    Motley Fool2 months ago

    Here's Why Fluidigm Shares Fell as Much as 14.4% Today

    The laboratory equipment manufacturer announced first-quarter 2019 operating results and a significant transaction.

  • Fluidigm (FLDM) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Fluidigm (FLDM) Q1 2019 Earnings Call Transcript

    FLDM earnings call for the period ending March 31, 2019.

  • Fluidigm (FLDM) Reports Q1 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Fluidigm (FLDM) Reports Q1 Loss, Tops Revenue Estimates

    Fluidigm (FLDM) delivered earnings and revenue surprises of -40.00% and 4.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Fluidigm: 1Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 44 cents per share. Losses, adjusted for one-time gains and costs, came to 14 cents per share. The company that makes equipment to ...

  • GlobeNewswire3 months ago

    Fluidigm Announces First Quarter 2019 Financial Results

    First quarter revenue increased 19 percent to $30.1 million Mass cytometry revenue growth of 110 percent in first quarter Strong mass cytometry and Imaging Mass Cytometry.

  • GlobeNewswire3 months ago

    Leading Cancer Center in Japan Selects Hyperion Imaging System to Expand Immuno-Oncology Research Studies in Colorectal Cancer

    Fluidigm Corporation (FLDM) announced today that the Group for Innovative Cancer Treatment Division of the National Cancer Center in Japan has expanded its clinical research in colorectal cancer using the Hyperion™ Imaging System to study regulatory T (Treg) cell proliferation in tumor tissue with the goal of discovering a novel target for immunotherapy.

  • Masimo Gets CE Mark for ANI Module, Enhances Root Platform
    Zacks3 months ago

    Masimo Gets CE Mark for ANI Module, Enhances Root Platform

    Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.

  • GlobeNewswire3 months ago

    Fluidigm Announces 8th Annual Mass Cytometry Summit

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will hold the 8th Annual Fluidigm Mass Cytometry Summit on June 20 and 21, 2019, at the Pinnacle Hotel Harbourfront in Vancouver, Canada. The Summit brings together translational researchers from around the world to discuss new mass cytometry research applications and best practices for identifying biomarker signatures in health and disease and accelerating therapeutic development. “We are excited to hold this year’s Summit right before CYTO® 2019,” said Chris Linthwaite, President and CEO of Fluidigm.

  • Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?
    Zacks3 months ago

    Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?

    Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.

  • Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks3 months ago

    Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.